Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Translational Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.
J Immunother Cancer. 2023 Apr;11(4). doi: 10.1136/jitc-2022-006195.
In clear cell renal cell carcinoma (ccRCC), tumor-associated macrophage (TAM) induction of CD8+T cells into a terminally exhausted state has been implicated as a major mechanism of immunotherapy resistance, but a deeper biological understanding is necessary.
Primary ccRCC tumor samples were obtained from 97 patients between 2004 and 2018. Multiplex immunofluorescence using lymphoid and myeloid markers was performed in seven regions of interest per patient across three predefined zones, and geospatial analysis was performed using Ripley's K analysis, a methodology adapted from ecology.
Clustering of CD163+M2 like TAMs into the stromal compartment at the tumor-stroma interface was associated with worse clinical stage (tumor/CD163+nK(75): stage I/II: 4.4 (IQR -0.5 to 5.1); stage III: 1.4 (IQR -0.3 to 3.5); stage IV: 0.6 (IQR -2.1 to 2.1); p=0.04 between stage I/II and stage IV), and worse overall survival (OS) and cancer-specific survival (CSS) (tumor/CD163+nK(75): median OS-hi=149 months, lo=86 months, false-discovery rate (FDR)-adj. Cox p<0.001; median CSS-hi=174 months, lo=85 months; FDR-adj. Cox p<0.001). An RNA-seq differential gene expression score was developed using this geospatial metric, and was externally validated in multiple independent cohorts of patients with ccRCC including: TCGA KIRC, and the IMmotion151, IMmotion150, and JAVELIN Renal 101 clinical trials. In addition, this CD163+ geospatial pattern was found to be associated with a higher TIM-3+ proportion of CD8+T cells, indicative of terminal exhaustion (tumor-core: 0.07 (IQR 0.04-0.14) vs 0.40 (IQR 0.15-0.66), p=0.05).
Geospatial clustering of CD163+M2 like TAMs into the stromal compartment at the tumor-stromal interface was associated with poor clinical outcomes and CD8+T cell terminal exhaustion.
在透明细胞肾细胞癌(ccRCC)中,肿瘤相关巨噬细胞(TAM)诱导 CD8+T 细胞进入终末耗竭状态,被认为是免疫治疗耐药的主要机制,但需要更深入的生物学理解。
本研究于 2004 年至 2018 年间从 97 名患者中获得了原发性 ccRCC 肿瘤样本。对每个患者的三个预设区域的七个感兴趣区域进行淋巴样和髓样标志物的多重免疫荧光检测,并使用 Ripley 的 K 分析进行地理空间分析,该方法源自生态学。
CD163+M2 样 TAM 聚集在肿瘤-基质界面的基质区与更差的临床分期相关(肿瘤/CD163+nK(75):I/II 期:4.4(IQR-0.5 至 5.1);III 期:1.4(IQR-0.3 至 3.5);IV 期:0.6(IQR-2.1 至 2.1);p=0.04 比较 I/II 期和 IV 期),且总生存期(OS)和癌症特异性生存期(CSS)更差(肿瘤/CD163+nK(75):中位 OS-高=149 个月,低=86 个月,错误发现率(FDR)-调整 Cox p<0.001;中位 CSS-高=174 个月,低=85 个月;FDR-调整 Cox p<0.001)。使用这种地理空间度量开发了一个 RNA-seq 差异基因表达评分,并在包括 TCGA KIRC 以及 IMmotion151、IMmotion150 和 JAVELIN Renal 101 临床试验在内的多个独立的 ccRCC 患者队列中进行了外部验证。此外,还发现这种 CD163+的地理空间模式与更高比例的 TIM-3+CD8+T 细胞相关,提示终末耗竭(肿瘤核心:0.07(IQR 0.04-0.14)比 0.40(IQR 0.15-0.66),p=0.05)。
CD163+M2 样 TAM 在肿瘤-基质界面的基质区聚集与不良临床结局和 CD8+T 细胞终末耗竭有关。